Comparable stake leader
Adelene Q. Perkins
SEC ownership of INFINITY PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001113148.
Disclosed value leader
Adelene Q. Perkins
Comparable rows
0/12
Latest evidence
08 Sep 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Adelene Q. Perkins
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
08 Sep 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001113148
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of INFINITY PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Adelene Q. Perkins
Disclosed value leader
Adelene Q. Perkins
Comparable rows
0/12
Latest evidence
08 Sep 2023
3/4/5
Highest disclosed value: $83,421
12 rows are not safely comparable across share classes.
Showing 1-8 of 12 holder rows.
Quick read
Adelene Q. Perkins has the largest disclosed position value at $83.4K.
0 of 12 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Adelene Q. Perkins's linked filing trail.
Disclosed position value
Top 4
Adelene Q. Perkins
$83.4K
Anthony B. Evnin
$15.1K
Stephane Peluso
$2.6K
Brian Schwartz
$2.2K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 12 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Adelene Q. Perkins |
3/4/5
Director
|
—
class O/S missing
|
$83,421
1,191,738 shares
|
— | 08 Sep 2023 |
| Anthony B. Evnin |
3/4/5
Director
|
—
mixed-class rows
|
$15,078
260,403 shares
mixed-class rows
|
— | 16 Jun 2022 |
| Stephane Peluso |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
$2,594
37,052 shares
|
— | 02 Aug 2022 |
| Brian Schwartz |
3/4/5
Director
|
—
mixed-class rows
|
$2,164
75,919 shares
mixed-class rows
|
— | 16 Jun 2022 |
| Lawrence E. Bloch |
3/4/5
President
|
—
class O/S missing
|
—
335,000 shares
|
— | 11 Jan 2022 |
| Seth A. Tasker |
3/4/5
Chief Business Officer
|
—
class O/S missing
|
—
225,000 shares
|
— | 11 Jan 2022 |
| Sujay Kango |
3/4/5
Director
|
—
class O/S missing
|
—
90,000 shares
|
— | 30 Mar 2022 |
| Robert Ilaria Jr. |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
87,472 shares
|
— | 11 Jan 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 18 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to INFINITY PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Adelene Q. Perkins
Net 12M change
$0
Latest report
08 Sep 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Adelene Q. Perkins | Director | $83,421 | Mixed | 08 Sep 2023 | ||
| Anthony B. Evnin | Director | $15,078 | Mixed | 16 Jun 2022 | ||
| Stephane Peluso | Chief Scientific Officer | $2,594 | Mixed | 02 Aug 2022 | ||
| Brian Schwartz | Director | $2,164 | Mixed | 16 Jun 2022 | ||
| Richard Gaynor | Director | Mixed | 16 Jun 2022 | |||
| Norman C. Selby | Director | Mixed | 16 Jun 2022 | |||
| Robert Ilaria Jr. | Chief Medical Officer | Mixed | 11 Jan 2022 | |||
| Seth A. Tasker | Chief Business Officer | Mixed | 11 Jan 2022 | |||
| David W. Beier | Director | Mixed | 16 Jun 2022 | |||
| Lawrence E. Bloch | President | Mixed | 11 Jan 2022 | |||
| Sujay Kango | Director | Mixed | 30 Mar 2022 | |||
| Samuel Agresta | Director | Mixed | 16 Jun 2022 |
Recent insider transactions for INFINITY PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.